Skip to main content

Table 2 IQ in low risk randomisation groups (HDM versus intrathecal MTX)

From: The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI

 

Number of patients

Mean adjusted IQ*

(SD)

Difference in

means

(95% CI)

t-test

p-value

 

   HDM

IT MTX

   HDM

IT MTX

  

FSIQ

      

   3 years

   138

132

97.9

(16)

98.3

(16)

-0.4

(-4.4 : 3.5)

   0.8

   5 years

   116

104

99.5

(15)

100.9

(18)

-1.4

(-5.8 : 3.0)

   0.5

VIQ

      

   3 years

   138

132

97.8

(15)

98.2

(15)

-0.4

(-4.0 : 3.3)

   0.8

   5 years

   116

104

99.2

(14)

100.3

(17)

-1.1

(-5.2 : 3.0)

   0.6

PIQ

      

   3 years

   138

132

98.1

(17)

99.0

(17)

-1.0

(-5.0 : 3.1)

   0.6

   5 years

   116

104

100.2

(15)

101.3

(19)

-1.1

(-5.7 : 3.4)

   0.6

  1. *IQ adjusted for test by subtracting:
  2. 7.15 from each WPPSI-R full IQ.
  3. 3.79 from each WPPSI-R verbal IQ.
  4. 8.74 from each WPPSI-R performance IQ.